Response to Comments: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy DL36408

This article is a response summarizing comments received for the Draft LCD 'Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) DL36408' and does not itself specify coverage criteria. The document does not provide specific indications, exclusions, documentation requirements, or frequency limits; refer to the final LCD DL36408 or related policy documents for definitive coverage rules.